James Kahn

Publications

• A cross-sectional study of barriers to personal health record use among patients attending a safety-net clinic. Hilton JF, Barkoff L, Chang O, Halperin L, Ratanawongsa N, Sarkar U, Leykin Y, Muñoz RF, Thom DH, Kahn JS. PLoS One. 2012; 7 (2): e31888
• A piece of my mind. Next: text. Kahn JS, JAMA. 2012; 307 (17): 1807-8
• Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Science. 2010; 327 (5966): 697-701
• Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General Hospital. Kahn JS, Hilton JF, Van Nunnery T, Leasure S, Bryant KM, Hare CB, Thom DH. J Am Med Inform Assoc. 2010; 17 (2): 224-8
• Evidence for risk-stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. Taiwo B, Yanik EL, Napravnik S, Ryscavage P, Koletar SL, Moore R, Mathews WC, Crane HM, Mayerr K, Zinski A, Kahn JS, Eron JJ. AIDS. 2013
• A mentor development program for clinical translational science faculty leads to sustained, improved confidence in mentoring skills. Feldman MD, Steinauer JE, Khalili M, Huang L, Kahn JS, Lee KA, Creasman J, Brown JS. Clin Transl Sci. 2012; 5 (4): 362-7
• Characterizing HIV transmission networks across the United States. Aldous JL, Pond SK, Poon A, Jain S, Qin H, Kahn JS, Kitahata M, Rodriguez B, Dennis AM, Boswell SL, Haubrich R, Smith DM. Clin Infect Dis. 2012; 55 (8): 1135-43
• A Randomized Noninferiority Trial of Standard Versus Enhanced Risk Reduction and Adherence Counseling for Individuals Receiving Post-Exposure Prophylaxis Following Sexual Exposures to HIV Roland ME, Neilands TB, Krone MR, Coates TJ, Franses K, Chesney MA, Kahn JS, Martin JN.. Clin Infect Dis. 2011; 53 (1): 76-83
• Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, Busang L, Blower S. Sci Rep. 2011: 1 185
• Mortality Among Antiretroviral-Eligible Patients in an Urban Public Clinic Dowdy DW, Geng EH, Christopoulos KA, Kahn JS, Hare CB, Wlodarczyk D, Havlir DV. J Acquir Immune Defic Syndr. 2011; 57 (4): 297-300
• The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. Clin Infect Dis. 2011; 53 (10): 1008-14
• Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load Poon A, Frost S, Aldous J, Mathews W, Kitahata M, Rodriguez B, Saag M, Boswell S, Kahn J, Haubrich R. PLoS Med. 2011; 6 (6): e21189
• Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? Wagner BG, Kahn JS, Blower S. AIDS. 2010; 13 (24): 775-6
• The potential roles of mHealth in developing economies: Can they be realized? Kahn JG, Yang J, Kahn JS. Health Affairs. 2010; 29 (2): 254-61
• Mentoring early-career scientists for HIV research careers Kahn JS, Greenblatt RM. Am J Public Health. 2009; 99 (1 Suppl): S37-42
• Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. Breban R, Napravnik S, Kahn J, Blower S. BMC Public Health. 2009; 9 (Suppl 1): 11
• Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program. Feldman MD, Huang L, Guglielmo BJ, Jordan R, Kahn J, Creasman JM, Wiener-Kronish JP, Lee KA, Tehrani A, Yaffe K, Brown JS. Clin Transl Sci. 2009; 2 (3): 216-21
• What it takes: characteristics of the ideal personal health record Kahn JS, Aulakh V, Bosworth A. Health Affairs. 2009; 28 (2): 369-76
• Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, Lober WB, Van Rompaey SE, Crane HM, Moore RD, Bertram M, Kahn JO, Saag MS. Int J Epidemiol. 2008; 37 (5): 948-55
• Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research. Kahn J, Des Jarlais CD, Dobkin L, Barrs SF, Greenblatt RM. J Acquir Immune Defic Syndr. 2008: 47 Suppl 1 S5-9
• Signposts along the NIH roadmap for reengineering clinical research: lessons from the Clinical Research Networks initiative Williams RL, Johnson SB, Greene SM, Larson EB, Green LA, Morris A, Confer D, Reaman G, Madigan R, Kahn J; Principal Investigators of Clinical Research Networks Initiative. Arch Intern Med. 2008; 168 (17): 1919-25
• Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network.. AIDS Res Hum Retroviruses. 2006; 22 (7): 678-83
• Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. J Virol. 2006; 80 (21): 10407-18
• Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Wilson DP, Kahn J, Blower SM. Proc Natl Acad Sci USA. 2006; 103 (38): 14228-33
• Seroconversion following nonoccupational postexposure prophylaxis against HIV. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN. Clin Infect Dis. 2005; 41 (10): 1507-13
• The antiretroviral rollout & drug resistant HIV in Africa: insights from empirical data & theoretical models. Blower S, Bondine E, Kahn J, McFarland W. AIDS Res Hum Retroviruses. 2005; 19 (1): 1-14
• Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. AIDS. 2004; 18 (15): 2065-73
• Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Arch Intern Med. 2004; 164 (1): 46-54
• HIV RNA testing in the context of nonoccupational postexposure prophylaxis. Roland ME, Elbeik TA, Kahn JO, Bamberger JD, Coates TJ, Krone MR, Katz MH, Busch MP, Martin JN. J Infect Dis. 2004; 190 (3): 598-604
• Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM. J Infect Dis. 2004; 190 (2): 251-6
• Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. Blood. 2004; 104 (4): 942-7
• Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. Martinez-Mariño B, Shiboski S, Hecht FM, Kahn JO, Levy JA. AIDS. 2004; 18 (15): 1991-9
• Primary HIV Infection. Hare CB, Kahn JO. Curr Infect Dis Rep. 2004; 6 (1): 65-71
• Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, Chesney MA, Franses K, Kahn JO, Coates TJ, Katz MH. AIDS. 2004; 18 (5): 787-92
• Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. Smith DE, Kaufmann GR, Kahn JO, Hecht FM, Grey PA, Zaunders JJ, Cunningham PH, Carr A, Duncombe C, Quan DC, Petersen A, Cooper DA. AIDS Res Hum Retroviruses. 2003; 19 (3): 189-99
• Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD. AIDS. 2003; 17 (18): 2581-91
• Predicting the transmission of drug-resistant HIV: comparing theory with data. Blower SM, Aschenbach AN, Kahn JO. Lancet Infect Dis. 2003; 3 (1): 10-1
• Development of WF10, a novel macrophage-regulating agent. McGrath MS, Kahn JO, Herndier BG. Curr Opin Investig Drugs. 2002; 3 (3): 365-73
• Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. Gascon RL, Narváez AB, Zhang R, Kahn JO, Hecht FM, Herndier BG, McGrath MS. J Acquir Immune Defic Syndr. 2002; 30 (2): 146-53
• Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Kahn J, Clin Infect Dis. 2002; 35 (11): 1382-7
• Time trends in primary HIV-1 drug resistance among recently infected persons. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. JAMA. 2002; 288 (2): 181-8
• Use of laboratory tests and clinical symptoms for identification of primary HIV infection. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Levy J, Kahn JO. AIDS. 2002; 16 (8): 1119-29
• Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD. J Exp Med. 2001; 193 (2): 169-80
• Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, Franses K, Coates TJ, Katz MH. J Infect Dis. 2001; 183 (5): 707-14
• Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy. Schito AM, Vittinghoff E, Hecht FM, Elkins MK, Kahn JO, Levy JA, Oksenberg JR. Blood. 2001; 97 (1): 214-20
• Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Antimicrob Agents Chemother. 2001; 45 (10): 2733-9
• Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. Roland ME, Martin JN, Grant RM, Hellmann NS, Bamberger JD, Katz MH, Chesney M, Franses K, Coates TJ, Kahn JO. J Infect Dis. 2001; 184 (12): 1608-12
• Predicting the unpredictable: transmission of drug-resistant HIV. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Nat Med. 2001; 7 (9): 1016-20
• Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C, van der Horst C. J Antimicrob Chemother. 2001; 48 (4): 507-13
• Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA.. Proc Natl Acad Sci USA. 2001; 98 (2): 597-602
• Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. JAMA. 2000; 284 (17): 2193-202
• From the cell to the community: AIDS research in California. The University of California Universitywide AIDS Research Program annual meeting, February 2000. Moss NE, Lemp G, Bluthenthal R, Goldsmith MA, Haubrich R, Kahn JO. West J Med. 2000; 173 (2): 119-24
• Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. Davey RT, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO. JAMA. 2000; 284 (2): 183-9
• Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley K. J Clin Microbiol. 2000; 38 (3): 1113-20
• Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC Jr, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. J Infect Dis. 2000; 182 (5): 1357-64
• Building and testing an effective HIV vaccine. Kahn J, West J Med. 1999 Nov-Dec; 171 (5-6): 363-5
• Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D. JAMA. 1999 Dec 22-29; 282 (24): 2305-12
• Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA. AIDS Res Hum Retroviruses. 1999; 15 (18): 1685-9
• Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, Talmadge JE, Heseltine P, Murcar N, Gendelman HE, Coleman R, Kelsey L, Beckner S, Winship D, Kahn J.. Vaccine. 1999; 17 (1): 64-71
• Initial treatment for HIV infection. When, why, and with what? Kahn JO, Adv Exp Med Biol. 1999: 458 229-37
• A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19 (4): 339-49
• Acute human immunodeficiency virus type 1 infection. Kahn JO, Walker BD. N Engl J Med. 1998; 339 (1): 33-9
• Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, Corey L, Fauci AS.. Nat Med. 1998; 4 (3): 341-5
• New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP. JAMA. 1998; 280 (1): 42-8
• Post-exposure prevention of HIV-1 infection. Kahn JO, Antivir Ther. 1998: 3 Suppl 4 45-7
• Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals Barker E, Kahn J, Fujimura S, Levy JA. AIDS Res Hum Retroviruses. 1998; 12 (8): 1117-8
• Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO. Antimicrob Agents Chemother. 1998; 42 (9): 2380-4
• Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. N Engl J Med. 1998; 339 (5): 307-11
• Success and Sadness Kahn JO, JAMA. 1998; 280 (1): 89
• HIV-1 protease inhibitors. A review for clinicians. Deeks SG, Smith M, Holodniy M, Kahn JO. JAMA. 1997; 277 (2): 145-53
• Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines Zolla-Pazner S,, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S. J Infect Dis. 1997; 175 (4): 764-74
• Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3 Spino C, Kahn JO; Dolin R; Phair JP. J Acquir Immune Defic Syndr. 1997: 15 346-55
• Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3. Spino C, Kahn JO, Dolin R, Phair JP. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 15 (5): 346-55
• Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. Chesney MA, Chambers DB, Kahn JO. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16 (4): 266-71
• Patterns of opportunistic infections in patients with HIV infection Finkelstein DM, Williams PL, Molenberghs G, Feinberg J, Powderly WG, Kahn J, Dolin R and Cotton D. J Acquir Immune Defic Syndr. 1996: 12 38-45
• Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine Aweeka FT, Kwong M; Mak M; al-Uzri A; Affrime M; Cutler D; Kahn J; Gambertoglio JG. J Clinical Pharm. 1996; 36 (1): 107-113
• Phase 1 study of combination therapy with L-697, 661 and zidovudine Schooley RT, Campbell TB; Kuritzkes DR; Blaschke T; Stein DS; Rosandich ME; Phair J; Pottage JC; Messari F; Collier A; Kahn, J for the ACTG 184 Protocol Team. j Acquir Immune Defic Syndr. 1996: 12 363-70
• Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. J Infect Dis. 1996; 174 (4): 696-703
• The clinical use of didanosine. Kahn J, Adv Exp Med Biol. 1996: 394 245-56
• Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. Kahn JO, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, Sinangil F. J Infect Dis. 1995; 171 (5): 1343-7
• HIV care: a changing health care system. Kahn JO, Smith MD. J Acquir Immune Defic Syndr Hum Retrovirol. 1995: 8 Suppl 1 S1-3
• HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, et al.. Cell Mol Biol. 1995; 41 (3): 401-7
• Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. J Infect Dis. 1995; 171 (5): 1172-9
• Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group. Paredes J, Kahn JO, Tong WP, Feldstein ML, Lin S, Bennett JM, Metroka CE, Ratner L, Krown SE. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 9 (2): 138-44
• Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. Ann Intern Med. 1995; 122 (6): 401-8
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D. J Infect Dis. 1994; 170 (5): 1288-91
• Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex. Kahn JO, Gorelick KJ, Gatti G, Arri CJ, Lifson JD, Gambertoglio JG, Bostrom A, Williams R. Antimicrob Agents Chemother. 1994; 38 (2): 260-7
• Vaccines directed against HIV: preventive and therapeutic strategies. Kahn JO, Birx DL. AIDS Clin Rev. 1993-1994: 213-38
• Neurological reactions in HIV-infected patients treated with trichosanthin. Garcia PA, Bredesen DE, Vinters HV, Graefin von Einsiedel R, Williams RL, Kahn JO, Byers VS, Levin AS, Waites LA, Messing RO. Neuropathol Appl Neurobiol. 1993; 19 (5): 402-5
• Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. Richardson D, Liou SH, Kahn JO. J Acquir Immune Defic Syndr. 1993; 6 (11): 1212-23
• A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G. N Engl J Med. 1992; 327 (9): 581-7
• A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. Kahn JO, Stites DP, Scillian J, Murcar N, Stryker R, Volberding PA, Naylor PH, Goldstein AL, Sarin PS, Simmon VF. AIDS Res Hum Retroviruses. 1992; 8 (8): 1321-5
• AIDS-associated Kaposi's sarcoma. Kahn JO, Northfelt DW, Miles SA. AIDS Clin Rev. 1992: 261-80
• CD4 immunoadhesins in anti-HIV therapy: new developments. Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A. Int J Cancer Suppl. 1992: 7 69-72
• Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA. J Clin Oncol. 1991; 9 (6): 929-40
• Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO. J Acquir Immune Defic Syndr. 1991; 4 (9): 839-46
• Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. Antimicrob Agents Chemother. 1991; 35 (12): 2531-7
• Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Hodges TL, Kahn JO, Kaplan LD, Groopman JE, Volberding PA, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE. Antimicrob Agents Chemother. 1991; 35 (12): 2580-6
• Treatment of AIDS-related Kaposi's sarcoma. Northfelt DW, Kahn JO, Volberding PA. Hematol Oncol Clin North Am. 1991; 5 (2): 297-310
• AIDS-associated Kaposi's sarcoma. Kahn JO, AIDS Clin Rev. 1990: 115-28
• The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. Kahn JO, Kaplan LD, Gambertoglio JG, Bredesen D, Arri CJ, Turin L, Kibort T, Williams RL, Lifson JD, Volberding PA. AIDS. 1990; 4 (12): 1197-204
• The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Kahn JO, Allan JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, Izu AE, Mordenti J, Sherwin JE, Groopman JE. Ann Intern Med. 1990; 112 (4): 254-61
• Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, Abrams DI. J Acquir Immune Defic Syndr. 1989; 2 (3): 217-23